NCT04661852 2023-02-15
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
Phase 1 Completed
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Teva Branded Pharmaceutical Products R&D, Inc.
Duke University
University of Chicago